Cargando…

Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study

AIMS/INTRODUCTION: Differences in the glucose‐lowering mechanisms of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have been noted. Clarifying these differences could facilitate the choice of optimal drugs for individuals with type 2 diabetes and requires investigation in a clinical setting....

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuwata, Hitoshi, Yabe, Daisuke, Murotani, Kenta, Fujiwara, Yuuka, Haraguchi, Takuya, Kubota, Sodai, Kubota‐Okamoto, Saki, Usui, Ryota, Ishitobi, Minori, Yamazaki, Yuji, Hamamoto, Yoshiyuki, Kurose, Takeshi, Seino, Yusuke, Yamada, Yuichiro, Seino, Yutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668059/ https://www.ncbi.nlm.nih.gov/pubmed/34022121 http://dx.doi.org/10.1111/jdi.13598

Ejemplares similares

Relationship between deterioration of glycated hemoglobin‐lowering effects in dipeptidyl peptidase‐4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes
por: Kuwata, Hitoshi, et al.
Publicado: (2017)

Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β‐cell function and the achievement of the glycated hemoglobin target 1 year after initiation
por: Usui, Ryota, et al.
Publicado: (2017)

Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β‐cell function and the achievement of the HbA1c target 1 year after initiation
por: Usui, Ryota, et al.
Publicado: (2018)

Effects of physician’s diabetes self‐management education using Japan Association of Diabetes Education and Care Diabetes Education Card System Program and a self‐monitoring of blood glucose readings analyzer in individuals with type 2 diabetes: An exploratory, open‐labeled, prospective randomized clinical trial
por: Tanaka, Nagaaki, et al.
Publicado: (2021)

Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial
por: Kuwata, Hitoshi, et al.
Publicado: (2015)

Incretin concept revised: The origin of the insulinotropic function of glucagon‐like peptide‐1 – the gut, the islets or both?
por: Yabe, Daisuke, et al.
Publicado: (2017)

Association of dipeptidyl peptidase‐4 inhibitor use and risk of pancreatic cancer in individuals with diabetes in Japan
por: Kubota, Sodai, et al.
Publicado: (2022)

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas
por: Seino, Yutaka, et al.
Publicado: (2013)

A Review of Recent Findings on Meal Sequence: An Attractive Dietary Approach to Prevention and Management of Type 2 Diabetes
por: Kubota, Sodai, et al.
Publicado: (2020)

Effects of DPP‐4 inhibitor linagliptin and GLP‐1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open‐label, 2‐arm parallel comparative, exploratory trial
por: Yabe, Daisuke, et al.
Publicado: (2016)

Sodium‐glucose co‐transporter‐2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open‐label, 3‐arm parallel comparative, exploratory study
por: Yabe, Daisuke, et al.
Publicado: (2017)

Regulation of amino acid metabolism and α‐cell proliferation by glucagon
por: Hayashi, Yoshitaka, et al.
Publicado: (2018)

Mental distress and health‐related quality of life among type 1 and type 2 diabetes patients using self‐monitoring of blood glucose: A cross‐sectional questionnaire study in Japan
por: Tanaka, Nagaaki, et al.
Publicado: (2018)

A novel RFX6 heterozygous mutation (p.R652X) in maturity‐onset diabetes mellitus: A case report
por: Imaki, Sakiho, et al.
Publicado: (2021)

Evaluation of large‐scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs
por: Kurose, Takeshi, et al.
Publicado: (2017)

Is caloric restriction enough to increase longevity? Fasting and circadian alignment
por: Hamamoto, Yoshiyuki, et al.
Publicado: (2023)

Little enhancement of meal‐induced glucagon‐like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls
por: Yabe, Daisuke, et al.
Publicado: (2010)

Carbohydrate‐induced secretion of glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1
por: Seino, Yusuke, et al.
Publicado: (2016)

Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity
por: Usui, Ryota, et al.
Publicado: (2019)

Retrospective analysis of safety and efficacy of insulin‐to‐liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β‐cell function
por: Usui, Ryota, et al.
Publicado: (2013)

Glucagon Receptor Signaling and Glucagon Resistance
por: Janah, Lina, et al.
Publicado: (2019)

Lifestyle changes as a result of COVID‐19 containment measures: Bodyweight and glycemic control in patients with diabetes in the Japanese declaration of a state of emergency
por: Tanaka, Nagaaki, et al.
Publicado: (2021)

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans
por: Nauck, Michael A., et al.
Publicado: (2011)

Incretin‐based drugs for type 2 diabetes: Focus on East Asian perspectives
por: Seino, Yutaka, et al.
Publicado: (2016)

The journey to understanding incretin systems: Theory, practice and more theory
por: Yabe, Daisuke, et al.
Publicado: (2019)

Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs
por: Yabe, D, et al.
Publicado: (2015)

Blockade of glucagon increases muscle mass and alters fiber type composition in mice deficient in proglucagon‐derived peptides
por: Ueno, Shinji, et al.
Publicado: (2023)

Glucagon contributes to liver zonation
por: Cheng, Xiping, et al.
Publicado: (2018)

Evaluation of skeletal muscle mass indices, assessed by bioelectrical impedance, as indicators of insulin resistance in patients with type 2 diabetes
por: Hirasawa, Yoshikazu, et al.
Publicado: (2019)

Stigma evaluation for diabetes and other chronic non‐communicable disease patients: Development, validation and clinical use of stigma scale – The Kanden Institute Stigma Scale
por: Tanaka, Nagaaki, et al.
Publicado: (2022)

The once‐daily human glucagon‐like peptide‐1 analog, liraglutide, improves β‐cell function in Japanese patients with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2012)

Analysis of factors influencing postprandial C‐peptide levels in Japanese patients with type 2 diabetes: Comparison with C‐peptide levels after glucagon load
por: Funakoshi, Shogo, et al.
Publicado: (2011)

Fructose induces glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and insulin secretion: Role of adenosine triphosphate-sensitive K(+) channels
por: Seino, Yusuke, et al.
Publicado: (2015)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia
por: Umapathysivam, Mahesh M., et al.
Publicado: (2014)

Elevation of Fasting GLP-1 Levels in Child and Adolescent Obesity: Friend or Foe?
por: Kubota, Sodai, et al.
Publicado: (2021)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
por: Murakami, Takaaki, et al.
Publicado: (2020)

Predicting efficacy of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels
por: Iwasaki, Masahiro, et al.
Publicado: (2012)

Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression
por: Bomholt, Anna Billeschou, et al.
Publicado: (2022)

A case of familial hypocalciuric hypercalcemia type 1 due to CASR p.Pro55Leu mutation
por: Sumida, Akira, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fr1t8h2eaeb0lmo2brkf5ia9f7